Filana Therapeutics, Inc. SEC filings FLNA
Filana Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Nov 9, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 3, 2025 | — |
| 25-NSE | Delisting notice | May 3, 2024 | — |
| CERT | Filing | Jan 3, 2024 | — |
| 8-A12B | Filing | Jan 3, 2024 | — |
| 8-A12G | Filing | Jan 2, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2023 | — |
| CORRESP | Letter to the SEC | Aug 10, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 28, 2023 | — |
| EFFECT | Filing | May 5, 2020 | — |
| CORRESP | Letter to the SEC | May 1, 2020 | — |
| CORRESP | Letter to the SEC | Apr 9, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2020 | — |
| EFFECT | Filing | Jan 30, 2019 | — |
| CORRESP | Letter to the SEC | Jan 28, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2018 | — |
| D | Filing | Aug 30, 2018 | — |
| EFFECT | Filing | Jul 31, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2017 | — |
| CT ORDER | Filing | Apr 12, 2016 | — |
| EFFECT | Filing | Mar 12, 2014 | — |
| 8-A12G/A | Form 8-a12g/a | Jun 20, 2013 | — |
| CT ORDER | Filing | May 22, 2013 | — |
| CT ORDER | Filing | May 22, 2013 | — |
| CT ORDER | Filing | Mar 8, 2012 | — |
| CT ORDER | Filing | Aug 26, 2010 | — |
| EFFECT | Filing | Aug 10, 2010 | — |
| CORRESP | Letter to the SEC | Aug 6, 2010 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2010 | — |
| 8-A12G/A | Amendment no. 2 to form 8-a12g | Feb 2, 2010 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2010 | — |
| CORRESP | Letter to the SEC | Dec 18, 2009 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2009 | — |
| CORRESP | Letter to the SEC | Dec 4, 2009 | — |
| CORRESP | Letter to the SEC | Nov 25, 2009 | — |
| UPLOAD | Letter from the SEC | Nov 9, 2009 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FLNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1069530
- Former names
- CASSAVA SCIENCES INC (until Feb 19, 2026); PAIN THERAPEUTICS INC (until Mar 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.